A contemporary viewpoint on 'aspirin resistance'. (Q37989558)

26 August 2017

A contemporary viewpoint on 'aspirin resistance'. (English)

1 reference

26 August 2017

1 reference

4

Gregory Y H Lip

1 reference

26 August 2017

2

Eduard Shantsila

1 reference

26 August 2017

3

Andrew Blann

1 reference

26 August 2017

1

Nadzeya Kuzniatsova

1 reference

PubMed ID

22380694

26 August 2017

language of work or name

English

0 references

publication date

1 March 2012

1 reference

26 August 2017

1 reference

26 August 2017

44

1 reference

26 August 2017

8

1 reference

26 August 2017

773-783

1 reference

Aspirin resistance: definition, mechanisms and clinical read-outs

26 August 2017

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.605388

Aspirin and clopidogrel: efficacy, safety, and the issue of drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.605388

Towards a definition of aspirin resistance: a typological approach

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.605388

More on aspirin resistance: position paper of the Working Group on Aspirin Resistance. Proposal for a Laboratory Test Guiding Algorithm

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.605388

Interindividual variability in the response to oral antiplatelet drugs: a position paper of the Working Group on antiplatelet drugs resistance appointed by the Section of Cardiovascular Interventions of the Polish Cardiac Society, endorsed by the Wo

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.605388

Scientific and therapeutic advances in antiplatelet therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.605388

Assessment, mechanisms, and clinical implication of variability in platelet response to aspirin and clopidogrel therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.605388

Variability in platelet responsiveness to clopidogrel among 544 individuals.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.605388

Influence of aspirin resistance on platelet function profiles in patients on long-term aspirin and clopidogrel after percutaneous coronary intervention

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.605388

Variability in platelet aggregation following sustained aspirin and clopidogrel treatment in patients with coronary heart disease and influence of the 807 C/T polymorphism of the glycoprotein Ia gene

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.605388

Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.605388

Platelet response to low-dose enteric-coated aspirin in patients with stable cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.605388

Rapid stimulation of tyrosine phosphorylation signals downstream of G-protein-coupled receptors for thromboxane A2 in human platelets.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.605388

Evaluation of platelet function in aspirin treated patients with CAD

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.605388

Biological effects of aspirin and clopidogrel in a randomized cross-over study in 96 healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.605388

Residual arachidonic acid-induced platelet activation via an adenosine diphosphate-dependent but cyclooxygenase-1- and cyclooxygenase-2-independent pathway: a 700-patient study of aspirin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.605388

Optical platelet aggregation versus thromboxane metabolites in healthy individuals and patients with stable coronary artery disease after low-dose aspirin administration

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.605388

Aspirin resistance detected with aggregometry cannot be explained by cyclooxygenase activity: involvement of other signaling pathway(s) in cardiovascular events of aspirin-treated patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.605388

Estimated rate of thromboxane secretion into the circulation of normal humans

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.605388

Paired analysis of urinary thromboxane B2 metabolites in humans.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.605388

Cyclooxygenase-2 in human platelets as a possible factor in aspirin resistance.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.605388

Platelet function testing in cardiovascular diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.605388

Measuring antiplatelet drug effects in the laboratory

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.605388

Resistance to antiplatelet drugs: molecular mechanisms and laboratory detection

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.605388

A comparison of six major platelet function tests to determine the prevalence of aspirin resistance in patients with stable coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.605388

A comparison of platelet function tests and thromboxane metabolites to evaluate aspirin response in healthy individuals and patients with coronary artery disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.605388

Assessment of aspirin resistance varies on a temporal basis in patients with ischaemic heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.605388

Screening for aspirin resistance in stable coronary artery patients by three different tests

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.605388

Variability in response to aspirin: do we understand the clinical relevance?

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.605388

Prevalence of persistent platelet reactivity despite use of aspirin: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.605388

Platelet function measured by VerifyNow identifies generalized high platelet reactivity in aspirin treated patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.605388

Aspirin "resistance" and risk of cardiovascular morbidity: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.605388

Association of laboratory-defined aspirin resistance with a higher risk of recurrent cardiovascular events: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.605388

Use of the PFA-100 closure time to predict cardiovascular events in aspirin-treated cardiovascular patients: a systematic review and meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.605388

Association of cyclooxygenase-1-dependent and -independent platelet function assays with adverse clinical outcomes in aspirin-treated patients presenting for cardiac catheterization

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.605388

Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.605388

Incomplete inhibition of thromboxane biosynthesis by acetylsalicylic acid: determinants and effect on cardiovascular risk

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.605388

Why are some individuals resistant to the cardioprotective effects of aspirin? Could it be thromboxane A2?

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.605388

Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.605388

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.605388

High on-treatment platelet reactivity by more than one agonist predicts 12-month follow-up cardiovascular death and non-fatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.605388

A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.605388

Aspirin and clopidogrel drug response in patients undergoing percutaneous coronary intervention: the role of dual drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.605388

Incidence and clinical impact of dual nonresponsiveness to aspirin and clopidogrel in patients with drug-eluting stents.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.605388

Relationship between aspirin and clopidogrel responses in acute coronary syndrome and clinical predictors of non response

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.605388

Clinical predictors of dual aspirin and clopidogrel poor responsiveness in stable cardiovascular patients from the ADRIE study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.605388

The role of aspirin in cardiovascular prevention: implications of aspirin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.605388

Narrative review: aspirin resistance and its clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.605388

Antithrombotic properties of aspirin and resistance to aspirin: beyond strictly antiplatelet actions

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.605388

Pharmacogenetics of aspirin resistance: a comprehensive systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.605388

Compliance as a critical consideration in patients who appear to be resistant to aspirin after healing of myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.605388

Coagulation and innate immune responses: can we view them separately?

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.605388

Molecular and functional interactions among monocytes, platelets, and endothelial cells and their relevance for cardiovascular diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.605388

Specific binding of hypochlorite-oxidized HDL to platelet CD36 triggers proinflammatory and procoagulant effects

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.605388

Hypochlorite-oxidized LDL induces intraplatelet ROS formation and surface exposure of CD40L--a prominent role of CD36.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.605388

Platelet CD36 links hyperlipidemia, oxidant stress and a prothrombotic phenotype.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.605388

Relation of aspirin resistance to coronary flow reserve in patients undergoing elective percutaneous coronary intervention

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.605388

Leukocyte count is associated with increased platelet reactivity and diminished response to aspirin in healthy individuals with a family history of coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.605388

High residual platelet reactivity after clopidogrel: extent of coronary atherosclerosis and periprocedural myocardial infarction in patients with stable angina undergoing percutaneous coronary intervention

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.605388

Indices of platelet activation and the stability of coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.605388

Platelet function predicts myocardial damage in patients with acute myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.605388

Value of platelet reactivity in predicting response to treatment and clinical outcome in patients undergoing primary coronary intervention: insights into the STRATEGY Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.605388

Residual platelet activity is increased in clopidogrel- and ASA-treated patients with coronary stenting for acute coronary syndromes compared with stable coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.605388

In vitro aspirin resistance detected by PFA-100 closure time: pivotal role of plasma von Willebrand factor

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.605388

Prognostic value of circulating pregnancy-associated plasma protein levels in patients with chronic stable angina

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.605388

Association between C-reactive protein and angiographic restenosis after bare metal stents: an updated and comprehensive meta-analysis of 2747 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.605388

Usefulness of combined high-sensitive C-reactive protein and N-terminal-probrain natriuretic peptide for predicting cardiovascular events in patients with suspected coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.605388

C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.605388

Multiple biomarkers for the prediction of first major cardiovascular events and death

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.605388

Relationship between baseline inflammatory markers, antiplatelet therapy, and adverse cardiac events after percutaneous coronary intervention: an analysis from the clopidogrel for the reduction of events during observation trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.605388

Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.605388

Effect of obesity on platelet reactivity and response to low-dose aspirin.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.605388

Enhanced levels of soluble CD40 ligand and C-reactive protein in a total of 312 patients with metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.605388

Factors contributing to increased platelet reactivity in people with diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.605388

The possible association of in vivo leukocyte-platelet heterophilic aggregate formation and the development of diabetic angiopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.605388

C-reactive protein promotes monocyte-platelet aggregation: an additional link to the inflammatory-thrombotic intricacy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.605388

Increased synthesis of thromboxane A(2) and expression of procoagulant activity by monocytes in response to arachidonic acid in diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.605388

Meta-analysis of data from the six primary prevention trials of cardiovascular events using aspirin

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.605388

Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.605388

The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.605388

Aspirin resistance: position paper of the Working Group on Aspirin Resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.605388

Guidelines on myocardial revascularization

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.605388

Unstable angina, stroke, myocardial infarction and death in aspirin non-responders. A prospective, randomized trial. The ASCET (ASpirin non-responsiveness and Clopidogrel Endpoint Trial) design

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.605388

Tailored antiplatelet therapy can overcome clopidogrel and aspirin resistance--the BOchum CLopidogrel and Aspirin Plan (BOCLA-Plan) to improve antiplatelet therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.605388

Effect of high dose statin therapy on platelet function; statins reduce aspirin-resistant platelet aggregation in patients with coronary heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.605388

Effect of atorvastatin on platelet thromboxane A(2) synthesis in aspirin-treated patients with acute myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.605388

Treatment of aspirin-resistant patients with omega-3 fatty acids versus aspirin dose escalation

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.605388

Effects of polyunsaturated omega-3 fatty acids on responsiveness to dual antiplatelet therapy in patients undergoing percutaneous coronary intervention: the OMEGA-PCI (OMEGA-3 fatty acids after pci to modify responsiveness to dual antiplatelet thera

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.605388

Effect of antiplatelet therapy on inflammatory markers in atherothrombotic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.605388

ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention—Summary Article

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.605388

Predictive value of high sensitivity C-reactive protein in patients with ST-elevation myocardial infarction treated with percutaneous coronary intervention

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.605388

Enhanced Response of Blood Monocytes to In Vitro Lipopolysaccharide-Challenge in Patients With Recurrent Unstable Angina

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.605388

10.3109/07853890.2011.605388

21 January 2018

Identifiers

DOI

1 reference

26 August 2017

1 reference

PubMed ID

22380694